| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 09/07/2001 | WO2000075107A3 Bradykinin receptor antagonists |
| 09/07/2001 | WO2000054763A3 Pharmaceutical compositions comprising polymorphic forms of dehydroepiandrosterone |
| 09/07/2001 | CA2401697A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 09/07/2001 | CA2401667A1 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 09/07/2001 | CA2401659A1 Il-8 receptor antagonists |
| 09/07/2001 | CA2401357A1 Tissue degradation inhibitor agent |
| 09/07/2001 | CA2401175A1 Chordin-like-2 molecules and uses thereof |
| 09/06/2001 | US20010020013 Polymerase inhibitors |
| 09/05/2001 | EP1129199A2 Cell signaling polypeptides and nucleic acids |
| 09/05/2001 | EP1129193A1 Chemokine beta-7 |
| 09/05/2001 | EP1129191A1 Methods of diagnosing or treating neurological diseases |
| 09/05/2001 | EP1129183A2 Human glycine transporter type 2 |
| 09/05/2001 | EP1128829A1 Riluzole and alpha-tocopherol combination |
| 09/05/2001 | CN1311789A Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity |
| 09/04/2001 | US6284882 Myostatin gene promoter and inhibition of activation thereof |
| 09/04/2001 | US6284540 Neuronal trophic support and cell differentiation by introducing nucleotide sequence |
| 09/04/2001 | US6284268 Cyclosporin, synergistic |
| 09/04/2001 | US6284242 Method for enhancing myoblast migration and invasion in the context of gene therapy |
| 08/30/2001 | WO2001062923A2 Transporters and ion channels |
| 08/30/2001 | WO2001062789A1 Human polynucleotides, polypeptides, and antibodies |
| 08/30/2001 | WO2001062757A1 Novel compounds |
| 08/30/2001 | WO2001062744A2 Substituted piperazine compounds |
| 08/30/2001 | WO2001062736A1 Aryl fused azapolycyclic compounds |
| 08/30/2001 | WO2001062729A1 Novel compounds |
| 08/30/2001 | WO2001062728A1 Novel compounds |
| 08/30/2001 | WO2001062726A2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 08/30/2001 | WO2001062706A1 Aminoadamantane derivatives as therapeutic agents |
| 08/30/2001 | WO2001062236A2 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| 08/30/2001 | WO2001062233A2 Adenosine receptor modulators |
| 08/30/2001 | WO2000040733A9 Human cyclic nucleotide pdes |
| 08/30/2001 | CA2657986A1 Substituted piperazine compounds |
| 08/30/2001 | CA2401113A1 Transporters and ion channels |
| 08/30/2001 | CA2400435A1 Novel compounds |
| 08/30/2001 | CA2400434A1 Novel compounds |
| 08/30/2001 | CA2400293A1 Novel compounds |
| 08/30/2001 | CA2399442A1 New drug combinations |
| 08/30/2001 | CA2398275A1 Human polynucleotides, polypeptides, and antibodies |
| 08/29/2001 | EP1127129A1 Myosin heavy chain homolog |
| 08/29/2001 | EP1127071A1 Compounds with growth hormone releasing properties |
| 08/29/2001 | EP1126836A1 Benzamide potassium channel inhibitors |
| 08/29/2001 | CN1310718A Heterocyclic compound as inhibitors of rotamase enzymes |
| 08/29/2001 | CN1310716A Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 08/29/2001 | CN1310014A Lumbago treating Chinese medicine |
| 08/28/2001 | US6281352 Antiinflammatory agents |
| 08/28/2001 | US6280959 Zinc chelated cell surface receptor ligands for use as agonist of dimeric cell surface receptors; for example, 2-bis(2,5-bis(2-benzimidazolylimino)-3A,6A-diphenyl-1,2,3,3a, 4,5,6,6a-octahydroimidazo(4,5-d)imidazole-N,N')-zinc(II) |
| 08/28/2001 | US6280953 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| 08/28/2001 | CA2217888C Triacetin as a transdermal penetration enhancer |
| 08/28/2001 | CA2107552C Use of deprenyl to maintain, prevent loss, or recover nerve cell function |
| 08/23/2001 | WO2001061008A2 Polypeptides and nucleic acids encoding same |
| 08/23/2001 | WO2001060816A1 Kinase inhibitors |
| 08/23/2001 | WO2001060798A1 Amine derivatives for the treatment of apoptosis |
| 08/23/2001 | WO2001060392A1 Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
| 08/23/2001 | WO2001012775A3 25 human secreted proteins |
| 08/23/2001 | WO2001004116A3 Neurotrophic pyrrolidines and piperidines, and related compositions containing them |
| 08/23/2001 | US20010016603 Calcium formate for use as a dietary supplement |
| 08/23/2001 | US20010016583 Therapeutic application of pro-apoptotic benzodiazepines |
| 08/23/2001 | US20010016576 Administering pyrimidine nucleotide precursor where respiratory chain dysfunction is caused by mutation, deletion, or rearrangement of mitochondrial DNA, cytotoxic cancer chemotherapy agents, aging |
| 08/23/2001 | US20010016568 Zinc chelate dimeric cell surface receptor antagonist |
| 08/23/2001 | US20010016207 Compounds such as N-(1-(cyanomethylcarbamoyl)cyclohexyl)-4-(piperazin-1-yl)-benzamide |
| 08/23/2001 | CA2400374A1 Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
| 08/23/2001 | CA2400332A1 Polypeptides and nucleic acids encoding same |
| 08/23/2001 | CA2397651A1 Amine derivatives for the treatment of apoptosis |
| 08/22/2001 | EP1126027A1 Cell death inhibition by the caspase-12 activation inhibitor MAGE-3 |
| 08/22/2001 | EP1125941A1 Derivatives of 6-sulfamoyl-3-quinolyl phosphonic acids, process for their preparation and pharmaceutical compositions containing them |
| 08/22/2001 | EP1125925A1 Amine derivatives for the treatment of apoptosis |
| 08/22/2001 | EP1124959A1 Cell surface molecule-induced macrophage activation |
| 08/22/2001 | EP1124951A2 Human sorting nexins |
| 08/22/2001 | EP1124845A2 Phosphinate peptide analogs for the treatment of fibrotic disorders |
| 08/22/2001 | EP1124828A1 Pyrano, piperidino, and thiopyrano compounds and methods of use |
| 08/22/2001 | EP1124824A1 Chromenone and chromanone derivatives as integrin inhibitors |
| 08/22/2001 | EP1124797A1 N-arylsulfonyl amino acid omega amides |
| 08/22/2001 | EP1124794A1 Substituted 3,3-diamino-2-propenenitriles, their preparation and use |
| 08/22/2001 | EP1124779A1 Vitamin d analogues |
| 08/22/2001 | EP1124559A1 Compositions for the treatment and prevention of neurological and pathopsychological diseases |
| 08/22/2001 | EP1124551A2 Delta 9 tetrahydrocannabinol (delta 9 thc) solution metered dose inhalers and methods of use |
| 08/22/2001 | CN1309631A Aminomethylcarboxylic acid derivs |
| 08/21/2001 | US6277999 As chemical intermediate for preparation of drugs |
| 08/21/2001 | US6277875 Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
| 08/21/2001 | US6277861 For treatment and prophylaxis of nervous system disorders, psychological disorders, muscular disorders, drug addiction withdrawal, pain |
| 08/21/2001 | US6277839 Antiinflammatory agents, antipyretics, analgesics; side effect reduction |
| 08/21/2001 | US6277586 Used for detecting the presence of autoantibodies to glutamic acid decarboxylaes (gad) in a biological sample |
| 08/21/2001 | US6277373 Phosphatidylinositol 4,5-bisphosphate 5-phosphatase |
| 08/21/2001 | CA2184871C Anticonvulsive 1-ar(alk)ylimidazolin-2-ones, and process for making |
| 08/18/2001 | CA2337786A1 New derivatives of phosphonic 6-sulfamoyl-3-quinolyl acids, the process for the preparation thereof and the pharmaceutical compounds containing them |
| 08/16/2001 | WO2001059103A2 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression |
| 08/16/2001 | WO2001059072A1 Differentiation of bone marrow cells into neuronal cells and uses therefor |
| 08/16/2001 | WO2001058895A1 Benzofuran carboxamides and their therapeutic use |
| 08/16/2001 | WO2001058891A2 Piperazine and piperidine derivatives for treatment or prevention of neuronal damage |
| 08/16/2001 | WO2001058889A1 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| 08/16/2001 | WO2001058886A1 Dipeptide nitrile cathepsin k inhibitors |
| 08/16/2001 | WO2001058881A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 08/16/2001 | WO2001058852A2 (r)-2-aryl-propionamides, useful in the inhibition of il-8-induced chemiotaxis of neutrophils |
| 08/16/2001 | WO2001058472A2 Botulinum toxin pharmaceutical compositions |
| 08/16/2001 | WO2001010413A3 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers |
| 08/16/2001 | WO2001010381A3 Methods for treating or preventing pain and anxiety |
| 08/16/2001 | WO2001007628A3 Human synthetases |
| 08/16/2001 | WO2001007435A3 N-(indolcarbonyl-)piperazin derivatives als 5-ht2a-receptor ligands |
| 08/16/2001 | WO2001006989A3 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 08/16/2001 | WO2001004354A3 Use of ras inhibitors of inhibiting muscle atrophy |
| 08/16/2001 | WO2001002569A3 Human immune response molecules |